Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 894.

https://doi.org/10.1182/blood-2023-174510

Published: 2023

Journal Articles

Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)

Mendel Goldfinger, Zhen-Huan Hu, Aaron P. Rapoport, Tanya Siddiqi, Lazaros J. Lekakis, Marcelo C Pasquini, Shilpa Shahani, Elande Baro, Jin Xie, Qinghua Song, Fang Sun, Hairong Xu, Frederick L. Locke

Blood (2022) 140 (Supplement 1): 9520–9522.

https://doi.org/10.1182/blood-2022-166510

Published: 2022

Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood (2022) 140 (Supplement 1): 1852–1855.

https://doi.org/10.1182/blood-2022-162421

Published: 2022

Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini

Blood (2022) 140 (Supplement 1): 7512–7515.

https://doi.org/10.1182/blood-2022-155603

Published: 2022

Journal Articles

Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis

Javier Muñoz, Zhen-Huan Hu, Steve Kanters, Eve H. Limbrick-Oldfield, Harry Miao, Clare Spooner, Hairong Xu, Robin Sanderson

Blood (2022) 140 (Supplement 1): 4627–4629.

https://doi.org/10.1182/blood-2022-162582

Published: 2022

Journal Articles

The Comparison of Kte-X19 to Current Standards of Care: A Pre-Specified Synthetic Control Study Utilizing Individual Patient Level Data from Historic Clinical Trials (SCHOLAR-3)

Bijal D. Shah, Imi Faghmous, James Whitmore, Behzad Kharabi Masouleh, Hairong Xu

Blood (2021) 138 (Supplement 1): 3844.

https://doi.org/10.1182/blood-2021-146598

Published: 2021

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chavez

Blood (2021) 138 (Supplement 1): 739.

https://doi.org/10.1182/blood-2021-148009

Published: 2021

Journal Articles

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Heiner Zimmermann, MD, Hairong Xu, MD PhD, Arie Barlev, PharmD, Yang Zhang, PhD, Dhanalakshmi Thirumalai, Crystal Watson, MS, Ralf Ulrich Trappe, MD

Blood (2019) 134 (Supplement_1): 65.

https://doi.org/10.1182/blood-2019-124583

Published: 2019

Journal Articles

Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review

Hairong Xu, MD PhD, Crystal Watson, MS, Shan Ashton Garib, MA, Anna Forsythe, PharmD, MSc, MBA, Arie Barlev, PharmD

Blood (2018) 132 (Supplement 1): 4777.

https://doi.org/10.1182/blood-2018-99-113593

Published: 2018

Journal Articles

A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder

Hairong Xu, MD PhD, Anna Forsythe, PharmD, MSc, MBA, Arie Barlev, PharmD, Nazia Rashid, PharmD, Crystal Watson, MS

Blood (2018) 132 (Supplement 1): 5839.

https://doi.org/10.1182/blood-2018-99-113583

Published: 2018

Journal Articles

Risk of Patients Developing Post-Transplant Lymphoproliferative Disorder within the First Year after an Allogeneic Hemopoietic Stem Cell Transplant, 2011 to 2016: A US Claims Database Analysis

Arie Barlev, PharmD, Hairong Xu, MD PhD, Nicole Fulcher, MA, Crystal Watson, MS, Ila Sruti, MPH, Akshay Sudhindra, MD

Blood (2018) 132 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2018-99-113598

Published: 2018

Journal Articles

Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence

Crystal Watson, MS, Hairong Xu, MD PhD, Anna Forsythe, PharmD, MSc, MBA, Shan Ashton Garib, MA, Arie Barlev, PharmD

Blood (2018) 132 (Supplement 1): 5841.

https://doi.org/10.1182/blood-2018-99-113622

Published: 2018

Journal Articles

A Study of Symptom Burdens Related to Chemotherapy-Induced Anemia in Patients Diagnosed with Breast Cancer, Lung Cancer and Non-Hodgkin Lymphoma

Chun Chao, PhD, Leila Family, PhD MPH, Kimberly Cannavale, MSc, Andrew Pourmoussa, MD, Lanfang Xu, MSc, Mehta Bhakti, MD, Hairong Xu, MD PhD

Blood (2016) 128 (22): 5980.

https://doi.org/10.1182/blood.V128.22.5980.5980

Published: 2016

Journal Articles

A Risk Prediction Model for Severe Chemotherapy-Induced Anemia in Breast Cancer Patients

Chun Chao, PhD, Lanfang Xu, MSc, Leila Family, PhD MPH, Hairong Xu, MD PhD

Blood (2016) 128 (22): 2399.

https://doi.org/10.1182/blood.V128.22.2399.2399

Published: 2016

Journal Articles

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Sophie Park, MD PhD, Pierre Fenaux, MD PhD, Peter Greenberg, MD, Bhakti Mehta, MD MPH, Fiona Callaghan, PhD, Christopher Kim, PhD MPH, Dianne Tomita, PhD, Hairong Xu, MD PhD

Blood (2015) 126 (23): 5236.

https://doi.org/10.1182/blood.V126.23.5236.5236

Published: 2015

Journal Articles

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Derek Weycker, PhD, Xiaoyan Li, PhD, Rich Barron, M.S., Hongsheng Wu, PhD, Phuong Khanh Morrow, MD, Hairong Xu, MD, PhD, Maureen Reiner, M.S., Jacob Garcia, MD, Shivani Mhatre, M.S., Gary H. Lyman, MD MPH

Blood (2014) 124 (21): 4824.

https://doi.org/10.1182/blood.V124.21.4824.4824

Published: 2014

Journal Articles

Incidence of Chemotherapy Induced Anemia in Patients Diagnosed with Solid Tumors

Hairong Xu, MD, PhD, Lanfang Xu, MS, John H Page, MD ScD, Olivia Sattayapiwat, MS, Roberto Rodriguez, MD, Chun Chao, PhD

Blood (2014) 124 (21): 4822.

https://doi.org/10.1182/blood.V124.21.4822.4822

Published: 2014

NARROW

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis

The Comparison of Kte-X19 to Current Standards of Care: A Pre-Specified Synthetic Control Study Utilizing Individual Patient Level Data from Historic Clinical Trials (SCHOLAR-3)

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review

A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder

Risk of Patients Developing Post-Transplant Lymphoproliferative Disorder within the First Year after an Allogeneic Hemopoietic Stem Cell Transplant, 2011 to 2016: A US Claims Database Analysis

Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence

A Study of Symptom Burdens Related to Chemotherapy-Induced Anemia in Patients Diagnosed with Breast Cancer, Lung Cancer and Non-Hodgkin Lymphoma

A Risk Prediction Model for Severe Chemotherapy-Induced Anemia in Breast Cancer Patients

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Incidence of Chemotherapy Induced Anemia in Patients Diagnosed with Solid Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only